proinflammatory cytokine
proinflammatory cytokine
Overview
Proinflammatory cytokines are signaling molecules produced primarily by innate immune cells, including macrophages, microglia, and dendritic cells, that mediate acute inflammatory responses and immune activation. The principal members of this family include tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β), which act through specific receptor pathways to orchestrate immune cell recruitment, activation, and the systemic inflammatory cascade. These cytokines are essential for protective immune responses against pathogens and tissue injury; however, their chronic or excessive production contributes to pathological inflammation underlying numerous degenerative, metabolic, and neoplastic diseases. Proinflammatory cytokines function through key signaling cascades including the TLR4/NF-κB pathway and are intimately linked to inflammasome activation via NLRP3. Given their central role in both physiological immunity and disease pathogenesis, proinflammatory cytokines have emerged as major pharmaceutical targets for therapeutic intervention across neurodegenerative, cardiovascular, metabolic, and immune-mediated disorders.
Recent Publications Focus
Below is a summary of the newest research publications targeting proinflammatory cytokine (sorted by publication date).
Recent research has established interleukin-6 (IL-6) and interleukin-8 (IL-8) as critical biomarkers for disease severity assessment and clinical outcome prediction across diverse conditions. In pediatric Mycoplasma pneumoniae pneumonia, elevated serum IL-6 and IL-8 levels were significantly associated with severe disease manifestations and poor short-term clinical outcomes, with a combined diagnostic model incorporating these cytokines achieving an area under the receiver operating characteristic curve of 0.943 [42417864]. Similarly, IL-6 emerged as a candidate biomarker for ischemic stroke risk in prospective analyses, with higher circulating IL-6 levels significantly associated with stroke incidence, and a machine learning model incorporating IL-6 alongside five metabolites demonstrated good discriminatory performance in external validation cohorts [42167472]. IL-6 has also been identified as a hub gene in network pharmacology studies examining extracellular matrix remodeling in glioma, where radiogenomic analysis revealed IL-6 association with survival prediction [42127900]. In sepsis diagnosis, multiplexed electrochemical biosensing platforms enabling concurrent detection of IL-6, TNF-α, and interferon-gamma have been developed for rapid point-of-care assessment, with detection limits as low as 0.94 pg/mL for IL-6 [42384130].
Tumor necrosis factor-alpha (TNF-α) plays a central role in cancer pathogenesis and immune evasion, particularly in triple-negative breast cancer metastasis where tumor-associated macrophages secrete TNF-α alongside other cytokines to promote epithelial-to-mesenchymal transition, migration, and lung colonization [42319344]. Blocking TNF-α signaling has emerged as a therapeutic strategy: anti-TNF-α monoclonal antibodies have been reformulated for oral delivery in ulcerative colitis, suppressing colonic TNF-α, interleukin-1β (IL-1β), and myeloperoxidase levels [41985594], while adalimumab, a TNF-α inhibitor, has been approved for treatment of pyoderma gangrenosum [42107018]. In metabolic dysfunction-associated steatohepatitis, TNF-α significantly altered transcriptional profiles and induced pro-inflammatory signaling pathways while downregulating lipid metabolic processes [42332153]. IL-1β has been identified as a key mediator of squamous cell carcinoma invasion through senescent macrophage-derived senescence-associated secretory phenotypes, suggesting that targeting the glutamine metabolism-regulated IL-1β/IL-1R2 axis could suppress cancer invasion [42333921].
Proinflammatory cytokines IL-6, IL-1β, and TNF-α play instrumental roles in neuroinflammation and neurodegeneration. vorinostat, a histone deacetylase inhibitor, rescued cognitive deficits in lipopolysaccharide-induced neuroinflammation models by suppressing hippocampal expression of these cytokines through inhibition of the Toll-like receptor 4/nuclear factor-kappa B signaling pathway, with more pronounced improvements observed in female mice [42406171]. Network pharmacology analyses of gut microbiota-derived metabolites in Alzheimer's disease identified IL-6, nuclear factor-kappa B, and interleukin-1β as central hub genes enriched in immune-inflammatory responses [42406869]. Aging-related susceptibility to traumatic brain injury appears mediated by an age-dependent microglial dichotomy where an NLRP3 inflammasome-linked, interleukin-1β-dominated state dominates the aged brain, with pharmacological perturbation of these pathways and the repurposed drug Imeglimin improving survival outcomes [42294901]. In aluminum-induced neurodegeneration, trans-anethole mitigated cognitive deficits by downregulating NLRP3 inflammasome components and pro-inflammatory factors including TNF-α and IL-1β [42154340].
Diverse therapeutic strategies have demonstrated efficacy in modulating proinflammatory cytokine production across multiple disease contexts. electroacupuncture sessions significantly decreased serum IL-6, interferon-gamma, and IL-4 while increasing anti-inflammatory IL-10 in chronic low back pain patients [42133255], suggesting activation of purinergic signaling promotes a shift toward anti-inflammatory profiles. Herbal formulations including Shenling Baizhu Powder for ulcerative colitis and salvianolic acid compounds for cerebral ischemia-reperfusion injury exerted neuroprotective effects through multi-target suppression of IL-6, IL-1β, TNF-α, and associated signaling pathways [42089391, 42102961]. Strength training during chemotherapy in breast cancer patients altered serum IL-6 and IL-17 profiles despite minimal changes in autophagy-related proteins [42350900]. Novel delivery systems including nano-in-microalgae integrated hydrogels engineered for oral gene therapy silenced TNF-α expression in ulcerative colitis models, simultaneously attenuating pro-inflammatory cytokine cascades and restoring intestinal barrier integrity [41297477]. Across these interventions, downregulation of IL-6, IL-1β, and TNF-α expression consistently correlated with improvements in tissue pathology, immune homeostasis, and clinical outcomes.